ArticleInternational journal of particle therapy2025
Independent Review Organization and Proton Therapy: Multistate Analysis and Legal Procedural Strategies.
Article in International journal of particle therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Securing insurance authorization for proton therapy remains a challenge for many centers. When health insurance or employer-sponsored health plans deny coverage, Independent Review Organizations (IROs) can review proton therapy cases. However, despite providing an independent review pathway, IROs are often underutilized in securing approvals for care following a denial. Materials and Methods: We analyzed trends in IRO approvals, strategies, and legal procedures using publicly available data from California (CA), Washington (WA), and New York (NY). Results: The aggregate analysis of the 3 states revealed an IRO average approval rate for proton therapy of 42.1%, with varying trends across states. All 3 states showed increases in IRO approval rates over time, averaging annual increases of +5.0%, +2.3%, and +7.2% for CA, WA, and NY, respectively. Sarcoma showed the highest IRO approval rate at 84.6%, followed by GYN cancers at 55.6% and breast cancer at 51.4%. CNS tumors and lymphomas had moderate approval rates at 44.7% and 40.0% respectively. Head and neck cancers had a 33.3% approval rate, while thoracic malignancies were at 36.8%. The lowest IRO approval rate was seen in prostate cancer at 16.5%. Qualitative analysis revealed that referencing guidelines, discussing published studies, citing trial inclusion, and submitting personalized letters were associated with higher IRO approval rates. Conclusion: IRO reviews provide a more objective remedy for patients denied care through internal appeals, particularly for plans with historically unfavorable proton policies. Our study demonstrates that IRO appeals provide a valuable pathway to proton therapy access with higher overturn rates improving significantly in recent years. Nearly half of initially denied patients eventually received approval through this process. Proton centers should strategically utilize IRO reviews to increase patient access and improve approval chances.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.